Please login to the form below

Not currently logged in
Email:
Password:

Eisai takes Almirall's cinitapride to China

Almirall SA has signed an agreement with Eisai Co Ltd granting Eisai the marketing rights to Almirall's gastroprokinetic agent cinitapride in China

Almirall SA has signed an agreement with Eisai Co Ltd granting Eisai the marketing rights to Almirall's gastroprokinetic agent cinitapride in China. The Spain- and Japan-headquartered companies have common interests in the gastrointestinal area; as well as Almirall's antihistamine Ebastine, which Eisai has made available in China since 2001, the partners have other shared projects in the market.

Currently marketed in Spain and Mexico under the names Cidine, Blaston and Pemix, cinitapride, developed by Almirall, is an orthopramide with prokinetic activity on the gastrointestinal tract, which blocks the presynaptic serotonin receptors and has antidopaminergic activity. Its marked procholinergic action improves gastrointestinal motility.

In Spain cinitapride is indicated for treating mild to moderate dysmotility-type dyspepsia and as an adjunctive therapy for gastroesophageal reflux disease (GERD) in patients for whom proton pump inhibitor (PPI) therapy has been shown to be insufficient.

Almirall already has a significant presence in Japan, Korea and Australia. Partnering with Eisai to market cinitapride in China is another aspect of Almirall's strategy to expand its presence in the Asian market through the distribution of its main R&D medicines.

This is a key focus for Almirall, which dedicates 15 per cent of its human resources to R&D and 20 per cent of its total revenue to drug discovery, and — through its own drugs and licences — has a presence in more than 100 countries worldwide.

19th April 2010

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Market Access Transformation

Market Access Transformation (MAT), founded by industry veterans Baiju Aurora and Paul Howard, specializes in developing cutting edge technologies that...

Latest intelligence

patients
Retaining reader value in plain language summaries of clinical studies
Balancing the risk of misinterpretation with the public’s ability to understand simplified plain-language summaries...
Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?
Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...
Paris
Making Europe a leader in bioscience: boosting trust and opening minds
A vision of Paris as Europe’s leading hub for life sciences innovation...

Infographics